Search company, investor...

Cross Pharma


Acquired Unit - II | Acquired

About Cross Pharma

Cross Pharma imports original brand pharmaceuticals from a number of EU countries and sells them to pharmacies in Sweden. In June 2013, Cross Pharma was acquired by Unimedic. The valuation of Cross Pharma was undisclosed. Other terms of the deal were not released.

Headquarters Location

Blasieholmsgatan 2

Stockholm, 111 48,


+46 8 407 64 30

Missing: Cross Pharma's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Cross Pharma's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Cross Pharma

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Cross Pharma is included in 1 Expert Collection, including Pharma Supply Chain.


Pharma Supply Chain

1,258 items

Cross Pharma Frequently Asked Questions (FAQ)

  • Where is Cross Pharma's headquarters?

    Cross Pharma's headquarters is located at Blasieholmsgatan 2, Stockholm.

  • What is Cross Pharma's latest funding round?

    Cross Pharma's latest funding round is Acquired Unit - II.

  • Who are the investors of Cross Pharma?

    Investors of Cross Pharma include Unimedic and Medivir.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.